Status:
COMPLETED
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Lead Sponsor:
Pfizer
Conditions:
Colorectal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progre...
Eligibility Criteria
Inclusion
- Histologically documented colorectal cancer plus one of the following:
- Failure of one prior irinotecan- or oxaliplatin-containing regimen, or
- Adjuvant refractory to irinotecan- or oxaliplatin-containing regimen.
Exclusion
- Prior treatment in first line metastatic setting with more than one regimen
- Prior irradiation of more than 25% of bone marrow.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT00615056
Start Date
March 1 2008
End Date
April 1 2012
Last Update
April 19 2013
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
2
Pfizer Investigational Site
Antioch, California, United States, 94531
3
Pfizer Investigational Site
Los Angeles, California, United States, 90095-6984
4
Pfizer Investigational Site
Los Angeles, California, United States, 90095